Successful second allogeneic peripheral blood stem cell transplantation and donor lymphocyte infusion in patients with relapsed acute leukemia using the same donors as for the initial allogeneic bone marrow transplantation.

Abstract:

:We report the successful treatment of two acute lympho- blastic leukemia (ALL) patients who relapsed following allogeneic bone marrow transplantation (allo-BMT) with allogeneic peripheral blood sem cell transplantation(allo-PBSCT) and donor lymphocyte infusion (DLI) from the same HLA-identical related donors as those used for the first allo-BMT. The patients relapsed on days 154 and 351 from the initial allo-BMT, respectively. Since conventional reinduction chemotherapy failed, allo-PBSCT was undertaken while the patients were still myelosuppressed immediately after reinduction chemotherapy. To induce and/or enhance GVL effects following allo-PBSCT, we performed rapid tapering of CsA and added DLI. After allo-PBSCT and DLI, the patients maintained their complete remission at 55 and 48 months post allo-PBSCT, respectively. From these findings, allo-PBSCT and DLI may be a useful treatment strategy for acute leukemia relapsing after allo-BMT.

journal_name

Bone Marrow Transplant

authors

Ishikawa J,Maeda T,Kashiwagi H,Yoshida H,Takahashi I,Kawamoto SI,Yamada M,Kato H,Nishiura T,Tomiyama Y,Matsuzawa Y

doi

10.1038/sj.bmt.1704059

subject

Has Abstract

pub_date

2003-06-01 00:00:00

pages

1057-9

issue

11

eissn

0268-3369

issn

1476-5365

pii

1704059

journal_volume

31

pub_type

杂志文章
  • Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.

    abstract::Intermediate-dose salvage therapy is frequently given for relapsed and resistant lymphomas and is usually intensely myelosuppressive. In an attempt to reduce the haematological toxicity of miniBEAM, one of the commonly used salvage regimens, peripheral blood stem cell (PBSC) support was given to 21 consecutive patient...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Fielding AK,Goldstone AH,Sullivan AM,Watts MJ,Jamieson E,Linch DC

    更新日期:1996-09-01 00:00:00

  • Paecilomyces varioti fungemia in a bone marrow transplant patient.

    abstract::Paecilomyces varioti, a fungus resembling penicillium spp, has been described in conjunction with impaired host defence or foreign body implants. We report a case of Paecilomyces varioti catheter-related fungemia that occurred during neutropenia in an allogeneic BMT patient receiving antifungal prophylaxis with flucon...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Shing MM,Ip M,Li CK,Chik KW,Yuen PM

    更新日期:1996-02-01 00:00:00

  • Allogeneic marrow transplantation in non-Hodgkin's lymphoma.

    abstract::Nine individuals between 15 and 43 years of age with non-Hodgkin's lymphoma underwent allogeneic marrow transplantation following busulfan 16 mg/kg and cyclophosphamide 120 mg/kg. These individuals were not considered optimal candidates for autologous transplantation chiefly because of marrow involvement or resistance...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Copelan EA,Kapoor N,Gibbins B,Tutschka PJ

    更新日期:1990-01-01 00:00:00

  • Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients.

    abstract::Neutropenia following high-dose chemotherapy leads to a high incidence of infectious complications, of which central venous catheter-related infections predominate. Catheter-related infections and associated risk factors in 392 patients participating in a randomized adjuvant breast cancer trial and assigned to receive...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2008.195

    authors: Nieboer P,de Vries EG,Mulder NH,Rodenhuis S,Bontenbal M,van der Wall E,van Hoesel QG,Smit WM,Hupperets P,Voest EE,Nooij MA,Boezen HM,van der Graaf WT

    更新日期:2008-10-01 00:00:00

  • Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

    abstract::Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2015.205

    authors: Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

    更新日期:2016-01-01 00:00:00

  • Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation.

    abstract::We recently reported that adolescents and young adults (AYAs) with B-cell ALL receiving allogeneic hematopoietic cell transplantation (allo-HCT) have inferior survival compared with children, primarily because of greater TRM. We therefore hypothesized that in the setting of allo-HCT for AML, similar inferior outcomes ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.171

    authors: Burke MJ,Gossai N,Cao Q,Macmillan ML,Warlick E,Verneris MR

    更新日期:2014-02-01 00:00:00

  • Pregnancy after bone marrow transplantation for severe aplastic anemia.

    abstract::Two women suffering from severe aplastic anemia were treated by bone marrow transplantation (BMT). They became pregnant 17 and 40 months after the procedure. During the first 20 weeks of pregnancy, one of them continued to receive cyclosporin A (CSA) to prevent graft-versus-host disease. Her CSA serum levels during th...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schmidt H,Ehninger G,Dopfer R,Waller HD

    更新日期:1987-10-01 00:00:00

  • A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.

    abstract::We studied the effects of escalating doses of recombinant human IL-1 beta in patients receiving high-dose chemotherapy and ABMT for metastatic breast cancer or malignant melanoma. Sixteen patients received IL-1 beta, 4 to 32 ng/kg/day administered subcutaneously for 7 days beginning 3 h after bone marrow infusion. Thr...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1700633

    authors: Elkordy M,Crump M,Vredenburgh JJ,Petros WP,Hussein A,Rubin P,Ross M,Gilbert C,Modlin C,Meisenberg B,Coniglio D,Rabinowitz J,Laughlin M,Kurtzberg J,Peters WP

    更新日期:1997-02-01 00:00:00

  • Analysis of post-transplant chimerism by using a single amplification reaction of 38 Indel polymorphic loci.

    abstract::In order to detect chimerism after allogeneic hematopoietic SCT (HSCT), several methods have been developed. In this study we describe the use of a set of insertion/deletion (Indel) polymorphic loci to determine the level of donor cell engraftment. We analyzed 50 DNA samples from patients who had undergone HSCT, and a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.173

    authors: Santurtún A,Riancho JA,Yañez L,Santurtún M,Zarrabeitia MT

    更新日期:2014-11-01 00:00:00

  • Thrombotic microangiopathy following allogeneic bone marrow transplantation.

    abstract::Thrombotic microangiopathy is one of the complications of bone marrow transplantation and is related to other complications such as graft-versus-host disease, veno-occlusive disease, diffuse alveolar hemorrhage, and cytomegalovirus infection. Thrombotic microangiopathy occurred in three out of 12 patients who underwen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701890

    authors: Takatsuka H,Takemoto Y,Okamoto T,Fujimori Y,Tamura S,Wada H,Okada M,Kanamaru A,Kakishita E

    更新日期:1999-08-01 00:00:00

  • Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.

    abstract::In 2005, the National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) consensus project provided diagnosis and staging criteria, based mostly on clinical experience and expert opinion. These criteria were revised in 2014, aiming to provide enhanced specificity and clarity. However, the impact of 2...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/s41409-018-0224-3

    authors: Kerep AZ,Broome J,Pirsl F,Curtis LM,Steinberg SM,Mitchell SA,Cowen EW,Pichard DC,Joe GO,Comis LE,Mays JW,Datiles MB 3rd,Stratton P,Zolton J,Berger A,Hendricks J,Kenyon M,Baruffaldi J,Titarenko I,Pulanic D,Baird K

    更新日期:2019-01-01 00:00:00

  • Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.

    abstract::Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%. Stem cell mobilization may be difficult in these patients because of multiple lines of treatment known to seriously hamper stem cell recovery. Plerixafor significantly enhan...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2010.264

    authors: Kobold S,Isernhagen J,Hübel K,Kilic N,Bogner C,Frickhofen N,Bokemeyer C,Fiedler W

    更新日期:2011-08-01 00:00:00

  • Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.

    abstract::In the current study, we evaluated a combination of tacrolimus and mycophenolate mofetil (MMF) as GvHD prophylaxis in 50 patients undergoing truly nonmyeloablative (NM; 90 mg/m(2) fludarabine, 2 Gy TBI) hematopoietic SCT (HSCT) from unrelated donors. Median patient age was 51 years (range, 25-67 years). After a median...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.167

    authors: Zohren F,Schroeder T,Czibere A,Fenk R,Bruns I,Kondakci M,Saure C,Haas R,Kobbe G

    更新日期:2011-05-01 00:00:00

  • Allogeneic BMT in a patient with CML and prior disseminated infection by mycobacterium avium complex.

    abstract::A patient with chronic myeloid leukemia (CML) who developed a disseminated infection by mycobacterium avium complex (MAC) was successfully treated with rifampin, ethambutol, isoniazid, cycloserin and ciprofloxacin. Diagnosis was proven by histologic examination of hepatic biopsy and culture of the liver biopsy materia...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Hermida G,Richard C,Baro J,Garcia-Ruiz JC,Barreiro G,Fariñas C,Zubizarreta A

    更新日期:1995-07-01 00:00:00

  • T-cell depletion: from positive selection to negative depletion in adult patients.

    abstract::Clinical trials have shown that a strategy for haploidentical transplantation based on the infusion of high numbers of T-cell-depleted hematopoietic progenitor cells and no post-transplant immunosuppression controls graft rejection and GvHD in patients with acute leukemia. Overall, event-free survival compares favorab...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.88

    authors: Aversa F

    更新日期:2015-06-01 00:00:00

  • Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal.

    abstract::The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702043

    authors: Yeh SP,Hsueh EJ,Yu MS,Wu H,Wang YC

    更新日期:1999-12-01 00:00:00

  • No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients.

    abstract::Complications of CVCs in 382 consecutive patients receiving a stem cell transplantation (SCT) were analysed. Early complications were pneumothorax (3.6%), haematothorax (0.5%), dislocation (3%) and dysfunction (3.6%). Eighty-seven-associated infections (22%) were observed, leading to removal of the CVC in 26 patients....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702675

    authors: Lagro SW,Verdonck LF,Borel Rinkes IH,Dekker AW

    更新日期:2000-11-01 00:00:00

  • Concentration of bone marrow progenitor cells by separation on a Percoll gradient using the Haemonetics model 30.

    abstract::To perform an optimal ex vivo bone marrow purge, it is necessary to concentrate the bone marrow progenitor cells and to eliminate both the red blood cells and the polymorphonuclear leucocytes. To achieve this goal which cannot be accomplished by using the Haemonetics model 30 alone, we used the Haemonetics model 30 an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Humblet Y,Lefebvre P,Jacques JL,Bosly A,Feyens AM,Sekhavat M,Agaliotis D,Symann M

    更新日期:1988-01-01 00:00:00

  • Early infections in patients undergoing bone marrow or blood stem cell transplantation--a 7 year single centre investigation of 409 cases.

    abstract::Infections are a major cause of morbidity and mortality in patients undergoing high-dose therapy and subsequent autologous or allogeneic haemopoietic stem cell transplantation, despite the change from topical to systemic anti-infection prophylaxis and the introduction of growth factors and new antimicrobial drugs. We ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701614

    authors: Krüger W,Rüssmann B,Kröger N,Salomon C,Ekopf N,Elsner HA,Kaulfers PM,Mack D,Fuchs N,Dürken M,Kabisch H,Erttmann R,Zander AR

    更新日期:1999-03-01 00:00:00

  • Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia.

    abstract::Sickle cell anemia (SCA) remains associated with high risks of morbidity and early death. Allogeneic hematopoietic SCT (HSCT) is the only curative treatment for SCA. We report our experience with transplantation in a group of patients with the non-Black African variant and the Black African variant of SCA. This study ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.167

    authors: Lucarelli G,Isgrò A,Sodani P,Marziali M,Gaziev J,Paciaroni K,Gallucci C,Cardarelli L,Ribersani M,Alfieri C,De Angelis G,Armiento D,Andreani M,Testi M,Amato A,Akinyanju OO,Wakama TT

    更新日期:2014-11-01 00:00:00

  • Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.

    abstract::High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL treated with high-dose (HD) busulfan (Bu)-containing regimens. From 1980 to 2009, 215 patients aged >1 year with stage 4 N...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.75

    authors: Proust-Houdemont S,Pasqualini C,Blanchard P,Dufour C,Benhamou E,Goma G,Semeraro M,Raquin MA,Hartmann O,Valteau-Couanet D

    更新日期:2016-08-01 00:00:00

  • Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?

    abstract::Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2009.214

    authors: Freytes CO,Lazarus HM

    更新日期:2009-11-01 00:00:00

  • Expression of TNFalpha by CD3+ and F4/80+ cells following irradiation preconditioning and allogeneic spleen cell transplantation.

    abstract::The pathogenesis of acute graft-versus-host disease (aGVHD) includes tumor necrosis factor-alpha (TNFalpha) expression by macrophages and T cells. However, the temporal comparison of donor vs host cells to TNFalpha expression in response to irradiation conditioning and alloreactivity has not been reported. This study ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704362

    authors: Brown S,Konopa J,Zhou D,Thompson J

    更新日期:2004-02-01 00:00:00

  • Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.

    abstract::Superiority of single-donor apheresis platelets (SDAP) over pooled platelet concentrates (PPC) transfusions is largely assumed, but unproven. We hypothesized that prophylactic SDAP and PPC transfusions are clinically equivalent after allogeneic hematopoietic stem cell transplants (HSCT). We studied all transfusions ad...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705751

    authors: Gurkan E,Patah PA,Saliba RM,Ramos CA,Anderson BS,Champlin R,de Lima M,Lichtiger B

    更新日期:2007-09-01 00:00:00

  • Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours.

    abstract::Reverse transcriptase polymerase chain reaction (RT-PCR) was applied to evaluate the frequency of tumour cells in PBPC products from 15 high risk Ewing tumour (ET) patients who were treated according to EICESS 92 with high-dose chemotherapy (HDC) and stem cell rescue. Initial tumour cell contamination of the bone marr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701924

    authors: Fischmeister G,Zoubek A,Jugovic D,Witt V,Ladenstein R,Fritsch G,Höcker P,Gadner H,Kovar H

    更新日期:1999-08-01 00:00:00

  • Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia.

    abstract::From May 1985 to July 1989, 76 patients with leukemia (30 acute myelogenous leukemia, 24 acute lymphoblastic leukemia and 22 chronic myeloid leukemia) were randomized to receive either cyclosporin (CSP) alone (n = 39) or CSP combined with methotrexate (CSP + MTX, n = 37) for graft-versus-host disease (GVHD) prophylaxi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Mrsić M,Labar B,Bogdanić V,Nemet D,Pavletić Z,Plavsić F,Dobrić I,Marusić M,Francetić I,Kastelan A

    更新日期:1990-08-01 00:00:00

  • Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.

    abstract::Seventy consecutive patients with refractory or relapsed Hodgkin's disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytara...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701325

    authors: Lancet JE,Rapoport AP,Brasacchio R,Eberly S,Raubertas RF,Linder T,Muhs A,Duerst RE,Abboud CN,Packman CH,DiPersio JF,Constine LS,Rowe JM,Liesveld JL

    更新日期:1998-08-01 00:00:00

  • Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning.

    abstract::The optimal preparation for stem cell transplantation (SCT) in children with congenital immunodeficiencies is currently unknown. In all, 81 children with immunodeficiency underwent 82 SCTs using reduced-intensity conditioning (RIC). The incidence of significant GVHD was low; viral reactivation was prominent with an un...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704846

    authors: Veys P,Rao K,Amrolia P

    更新日期:2005-03-01 00:00:00

  • Early iron reduction programme for thalassaemia patients after bone marrow transplantation.

    abstract::Thirty thalassaemia patients received iron reduction starting at around 3 months post transplant. Sixteen received desferrioxamine and nine had phlebotomy, five patients had desferrioxamine followed by phlebotomy. The desferrioxamine group had higher serum ferritin levels at the start of iron reduction as compared to ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702212

    authors: Li CK,Lai DH,Shing MM,Chik KW,Lee V,Yuen PM

    更新日期:2000-03-01 00:00:00

  • Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.

    abstract::Thirty patients with relapsed pediatric solid tumors received high-dose carboplatin and etoposide with autologous marrow support in a dose-escalation trial. These patients had received extensive prior treatment, which included both cisplatin and etoposide in 25 cases. Six patient cohorts received carboplatin in doses ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Santana VM,Schell MJ,Williams R,Bowman LC,Thompson EI,Brenner MK,Mirro J Jr

    更新日期:1992-11-01 00:00:00